Drug Profile
TCV 114
Latest Information Update: 17 Jul 1998
Price :
$50
*
At a glance
- Originator Takeda
- Developer David Geffen School of Medicine at UCLA; Osaka University School of Medicine; Takeda
- Class Antihypertensives
- Mechanism of Action Angiotensin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 17 Jul 1998 Discontinued-Clinical for Hypertension in Japan (Unknown route)
- 17 Jul 1998 Discontinued-Clinical for Hypertension in USA (Unknown route)
- 08 Jun 1995 New profile